Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC lozenges

Executive Summary

FDA sanctifies term "lozenge" as the only acceptable name for solid oral dosage forms to be dissolved in the mouth. Statement is part of amendment to OTC antitussive products in the Oct. 2 Federal Register. The monograph had previously used the terms "lozenge" and "compressed tablet" interchangeably. Agency is also revising its definition of lozenge, in accordance with a new U.S. Pharmacopeial definition, to claify that oral antitussive drugs with intended systemic effects may be formulated as lozenges.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS016392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel